...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern rheumatology >Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.
【24h】

Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA.

机译：在一项大型观察性队列研究IORRA中，布西拉明在类风湿性关节炎患者中的疗效概况。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) in Japan. However, direct comparison of this drug with standard DMARDs including sulfasalazine (SASP) and methotrexate (MTX) has been scarcely reported. We therefore tried to evaluate the clinical efficacy of Buc by analyzing the database from the long-term observational cohort study IORRA (previously known as J-ARAMIS). The cross-sectional analysis revealed that responses to Buc treatment were better in males, patients with shorter duration of illness, and those who were rheumatoid factor-negative. In the longitudinal analysis, although there was no marked difference among the baseline variables of patients with Buc, SASP, and MTX, the percentage of patients exhibiting moderate or good response to treatment, as rated using the European League Against Rheumatism improvement criteria, was higher in the Buc group (41.0%)than in the MTX (32.6%) and SASP groups (25.6%). These data support Buc as a candidate for being a first-line drug for the treatment of patients with RA.
机译：Bucillamine（Buc）是在日本开发的一种疾病缓解性抗风湿药（DMARD），在日本已被用作治疗类风湿关节炎（RA）的一线DMARD之一。但是，几乎没有报道将该药物与标准DMARDs进行直接比较，包括柳氮磺吡啶（SASP）和甲氨蝶呤（MTX）。因此，我们试图通过分析长期观察性队列研究IORRA（以前称为J-ARAMIS）中的数据库来评估Buc的临床疗效。横断面分析显示，男性，病程较短的患者以及类风湿因子阴性的患者对Buc治疗的反应都更好。在纵向分析中，尽管Buc，SASP和MTX患者的基线变量之间无显着差异，但根据欧洲抗风湿病改善标准评估，对治疗表现出中度或良好反应的患者百分比更高Buc组（41.0％）比MTX组（32.6％）和SASP组（25.6％）高。这些数据支持Buc成为治疗RA患者的一线药物的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号